Carrolee Barlow Net Worth

Carrolee Barlow biography

Dr. Carrolee Barlow M.D. Ph.D. serves as Independent Director of the Company. Dr. Barlow is a renowned expert in neuroscience and neurodegeneration, rare diseases and clinical development of new therapies, and she is presently the Chief Medical Officer of E-Scape Bio, a position she has held since January 2019. Prior to E-Scape, Dr. Barlow served as Chief Executive Officer of the Parkinson's Institute, an independent nonprofit organization providing research, clinical trials and patient care for arkinson's and related disorders. There, she led all aspects of basic research, clinical research, and clinical care, as well as partnerships with biotech and pharmaceutical companies. She remains a member of the board of directors for the Parkinson's Institute and Clinical Center. Before joining the Parkinson's Institute in 2014, Dr. Barlow served as a consultant and advisor to a variety of biotechnology companies addressing neurologic, psychiatric, metabolic and rare genetic iseases. She was acting Chief Medical Officer at Amicus Therapeutics leading the execution, analysis and regulatory interactions that resulted in the approval of the first small-molecule therapy for Fabry disease (migalastat). She also led efforts that resulted in the first proof-of-concept clinical studies in patients for two novel biologic programs for Pompe and Fabry diseases. Previously, Dr. Barlow was a co-founder, Chief Scientific Officer and Chief Medical Officer of BrainCells Inc., advancing new therapeutic approaches for neurological and psychiatric disease, and worked at Merck Research Laboratories as Director of Molecular Neuroscience and worldwide leader of the Stroke and Neurodegeneration therapeutic areas. Earlier in her career, Dr. Barlow was a professor at the Salk Institute for Biological Studies, where she was a pioneer in the nascent field of neurogenomic medicine at The New York Hospital, Cornell Medical Center. She went on to earn a Ph.D. in molecular and developmental biology at the Karolinska Medical Nobel Institute in Stock

What is the salary of Carrolee Barlow?

As the Independent Director of Supernus Pharmaceuticals Inc, the total compensation of Carrolee Barlow at Supernus Pharmaceuticals Inc is $324,953. There are 11 executives at Supernus Pharmaceuticals Inc getting paid more, with Jack Khattar having the highest compensation of $8,123,130.

How old is Carrolee Barlow?

Carrolee Barlow is 56, he's been the Independent Director of Supernus Pharmaceuticals Inc since 2018. There are 13 older and 3 younger executives at Supernus Pharmaceuticals Inc. The oldest executive at Supernus Pharmaceuticals Inc is John Siebert, 80, who is the Independent Director.

What's Carrolee Barlow's mailing address?

Carrolee's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850.

Insiders trading at Supernus Pharmaceuticals Inc

Over the last 12 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell и Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.

What does Supernus Pharmaceuticals Inc do?

pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

Supernus Pharmaceuticals Inc executives and stock owners

Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jack Khattar,
  President, Chief Executive Officer, Secretary, Director
• Jack A. Khattar,
  Founder, Pres, CEO, Sec. & Director
• Stefan Schwabe,
  Executive Vice President - Research and Development, Chief Medical Officer
• Padmanabh Bhatt,
  Senior Vice President - Intellectual Property, Chief Scientific Officer
• Tami Martin,
  Senior Vice President - Regulatory Affairs
• Dr. Padmanabh P. Bhatt,
  Chief Scientific Officer & Sr. VP of Intellectual Property
• Tami T. Martin,
  Sr. VP of Regulatory Affairs
• Charles Newhall,
  Independent Chairman of the Board
• Frederick Hudson,
  Independent Director
• John Siebert,
  Independent Director
• Georges Gemayel,
  Independent Director
• Carrolee Barlow,
  Independent Director
• Frank Mottola,
  Senior Vice President, Quality, GMP Operations and Information Technology
• James Kelly,
  Chief Financial Officer, Executive Vice President
• Jeff Bozick,
  Sr. VP of Supply Chain
• Frank Mottola,
  Sr. VP of Quality, GMP Operations & Information Technology
• Kevin T. Anderson,
  Compliance Officer
• Timothy C. Dec,
  Sr. VP & CFO
• Dr. Jonathan Rubin,
  Sr. VP & Chief Medical Officer
• Dr. Bryan A. Roecklein,
  VP of Corp. Devel.
• Taylor Raiford,
  VP of Sales
• Dr. Todd Horich M.B.A., Ph.D.,
  VP of Marketing
• William A. Nuerge,
  Director
• M James Barrett,
  Director
• Victor Vaughn,
  Sr. VP of Sales
• Krishna Kittu Kolluri,
  10% owner
• Advisors Llcisaly Samuel Do...,
  
• Partners 11 Lp Nea,
  10% owner
• Forest Baskett,
  10% owner
• Michael Bigham,
  Director
• Peter J Barris,
  10% owner
• Enterprise Associates 11 Lp...,
  10% owner
• Scott D Sandell,
  10% owner
• Jones W. Bryan,
  VP of Business Development
• Management Ltd Abingworth,
  10% owner
• Advisors Llcorbimed Capital...,
  
• Michael B Sheffery,
  Director
• Gregory S Patrick,
  Sr. VP Chief Financial Officer
• Jonathan Rubin,
  SVP, Chief Medical Officer
• Timothy C Dec,
  Senior Vice-President & CFO
• Bethany Sensenig,
  Director